Skip to main content
Premium Trial:

Request an Annual Quote

Genomics Ltd. Raises $12.8M in Private Financing

NEW YORK (GenomeWeb) – Genomics Ltd. has raised £10.3 million ($12.8 million) in a private round of financing, according to a statement released today by one of its investors, the IP Group.

The firm, which is a spinout from the University of Oxford in the UK, is developing a platform for genomic sequence data analysis. Its founders include Oxford Professors Peter Donnelly, who also is director of the Wellcome Trust Centre for Human Genetics, and Gil McVean. It is chaired by David Norwood, who was one of the founders of Oxford Nanopore Technologies.

Investors in the round included the IP Group and the University of Oxford, as well as new investors Invesco Perpetual, Lansdowne Partners, Woodford Investment Management and the Wylie Family Trust. The IP Group said that its nearly 17 percent stake in Genomics Ltd. is valued at £4.3 million, and including the holdings of an affiliated fund its effective beneficial interest in the firm is approximately 19 percent.

Last month, Genomics Ltd. was one of 10 firms selected to continue to the next assessment phase of the UK's 100,000 Genomes Project.

The Scan

Genetic Risk Factors for Hypertension Can Help Identify Those at Risk for Cardiovascular Disease

Genetically predicted high blood pressure risk is also associated with increased cardiovascular disease risk, a new JAMA Cardiology study says.

Circulating Tumor DNA Linked to Post-Treatment Relapse in Breast Cancer

Post-treatment detection of circulating tumor DNA may identify breast cancer patients who are more likely to relapse, a new JCO Precision Oncology study finds.

Genetics Influence Level of Depression Tied to Trauma Exposure, Study Finds

Researchers examine the interplay of trauma, genetics, and major depressive disorder in JAMA Psychiatry.

UCLA Team Reports Cost-Effective Liquid Biopsy Approach for Cancer Detection

The researchers report in Nature Communications that their liquid biopsy approach has high specificity in detecting all- and early-stage cancers.